2019-12-23
Announcement on Application and Acceptance of Oseltamivir Phosphate for Oral Suspension
Our company and HETERO LABS LIMITED of India reached cooperation on Oseltamivir Phosphate for Oral Suspension at the beginning of this year.
More +
2019-12-23
Our company and HETERO LABS LIMITED of India reached cooperation on Oseltamivir Phosphate for Oral Suspension at the beginning of this year.
More +2019-11-26
On November 26, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd., Registration Department and R & D Department were relocated to the new office area
2019-11-26
On November 26, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd., Registration Department and R & D Department were relocated to the new office area
2019-06-19
On June 18, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd. signed a license and cooperation agreement with Hetero, India. High-level officials from both sides celebrated the successful signing of the contract along the beautiful Huangpu River.
2019-06-19
On June 18, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd. signed a license and cooperation agreement with Hetero, India. High-level officials from both sides celebrated the successful signing of the contract along the beautiful Huangpu River.
2019-06-18
Ms. Wu Guangmei, Chairman of Beimei Pharmaceuticals, was appointed by the Global Association of Scientific and Technological Services in Shanghai on June 17, 2019.
2019-06-18
Ms. Wu Guangmei, Chairman of Beimei Pharmaceuticals, was appointed by the Global Association of Scientific and Technological Services in Shanghai on June 17, 2019.
2019-02-12
At the beginning of the New Year, we have received the contract signed by Indian W Company
2019-02-12
At the beginning of the New Year, we have received the contract signed by Indian W Company
2018-11-29
20 November 2018,"Clinical Study on Efficacy, Safety and Economics of Sultamicillin for Suspension in the Treatment of Children with Mild to Moderate Acute Bacterial Lower Respiratory Tract Infection"
2018-11-29
20 November 2018,"Clinical Study on Efficacy, Safety and Economics of Sultamicillin for Suspension in the Treatment of Children with Mild to Moderate Acute Bacterial Lower Respiratory Tract Infection"
2018-11-06
After nearly half a year's preparation, Shenzhen Beimei Pharmaceutical Co., Ltd. recently officially approved the certification of "Intellectual Property Management System" organized by the state-designated regulatory certification body, and has successfully obtained the certification certificate.
2018-11-06
After nearly half a year's preparation, Shenzhen Beimei Pharmaceutical Co., Ltd. recently officially approved the certification of "Intellectual Property Management System" organized by the state-designated regulatory certification body, and has successfully obtained the certification certificate.
2018-02-26
At the beginning of the Spring, in brand new 2018, Beimei Pharmaceuticals also moved in a new office space.
2018-02-26
At the beginning of the Spring, in brand new 2018, Beimei Pharmaceuticals also moved in a new office space.
2017-10-24
On 18 October 2017, the multi-center clinical investigator meeting of sultamicillin for suspension was successfully held in Suzhou!
2017-10-24
On 18 October 2017, the multi-center clinical investigator meeting of sultamicillin for suspension was successfully held in Suzhou!
2017-01-03
On 24 December 2016, after the last two multi-center clinical study protocol discussions, the third multi-center clinical study protocol initiation meeting of sultamicillin for suspension was officially held in Shenzhen.
2017-01-03
On 24 December 2016, after the last two multi-center clinical study protocol discussions, the third multi-center clinical study protocol initiation meeting of sultamicillin for suspension was officially held in Shenzhen.